Fintel reports that Fcmi Parent has filed a 13D/A form with the SEC disclosing ownership of 23.49MM shares of Vaccinex Inc (VCNX). This represents 42.8% of the company.
In their previous filing dated November 29, 2022 they reported 19.35MM shares and 38.80% of the company, an increase in shares of 21.43% and an increase in total ownership of 4.00% (calculated as current – previous percent ownership).
What is the Fund Sentiment?
There are 38 funds or institutions reporting positions in Vaccinex. This is an increase of 4 owner(s) or 11.76% in the last quarter. Average portfolio weight of all funds dedicated to VCNX is 0.02%, an increase of 25.73%. Total shares owned by institutions increased in the last three months by 1.53% to 4,928K shares. The put/call ratio of VCNX is 0.04, indicating a bullish outlook.
What are Other Shareholders Doing?
IWC – iShares Micro-Cap ETF holds 44K shares representing 0.09% ownership of the company. In it’s prior filing, the firm reported owning 43K shares, representing an increase of 2.41%. The firm increased its portfolio allocation in VCNX by 27.68% over the last quarter.
FSMAX – Fidelity Extended Market Index Fund holds 168K shares representing 0.34% ownership of the company. In it’s prior filing, the firm reported owning 168K shares, representing a decrease of 0.16%. The firm decreased its portfolio allocation in VCNX by 41.65% over the last quarter.
Creative Planning holds 11K shares representing 0.02% ownership of the company. No change in the last quarter.
Vectors Research Management holds 10K shares representing 0.02% ownership of the company. No change in the last quarter.
Hnp Capital holds 10K shares representing 0.02% ownership of the company. No change in the last quarter.
Vaccinex Background Information
(This description is provided by the company.)
Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company’s lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that prevents immune infiltration into tumors and triggers chronic inflammation in the brain. The Company additionally intends to leverage its proprietary drug discovery platform, ActivMAb®, to create opportunities for future pipeline expansion and strategic collaborations, particularly by exploiting its unique capability to select high value antibodies against important multi-pass membrane receptors including GPCR and ion channels.
This article originally appeared on Fintel
Essential Tips for Investing: Sponsored
A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.
Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
